MARKET

ESPR

ESPR

Esperion Therape
NASDAQ
3.325
-0.075
-2.21%
Opening 11:05 02/09 EST
OPEN
3.410
PREV CLOSE
3.400
HIGH
3.410
LOW
3.260
VOLUME
470.15K
TURNOVER
--
52 WEEK HIGH
4.175
52 WEEK LOW
0.6925
MARKET CAP
794.89M
P/E (TTM)
-6.2057
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ESPR last week (0202-0206)?
Weekly Report · 7h ago
Bank of America Securities Remains a Sell on Esperion (ESPR)
TipRanks · 6d ago
Weekly Report: what happened at ESPR last week (0126-0130)?
Weekly Report · 02/02 09:19
Weekly Report: what happened at ESPR last week (0119-0123)?
Weekly Report · 01/26 09:19
Weekly Report: what happened at ESPR last week (0112-0116)?
Weekly Report · 01/19 09:20
Piper Sandler Sticks to Their Buy Rating for Esperion (ESPR)
TipRanks · 01/16 13:53
H.B. Fuller, Caledonia Mining And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga · 01/15 13:06
H.C. Wainwright Reaffirms Their Buy Rating on Esperion (ESPR)
TipRanks · 01/13 11:46
More
About ESPR
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

Webull offers Esperion Therapeutics Inc stock information, including NASDAQ: ESPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ESPR stock methods without spending real money on the virtual paper trading platform.